
NAFDAC: Camosunate Not Banned in Nigeria, Refutes Social Media Claims
Summary
- NAFDAC has dismissed social media claims that Camosunate, an antimalarial drug, has been banned in Nigeria.
- The agency clarified that neither Camosunate nor medicines containing the artesunate-amodiaquine combination have ever been prohibited.
- NAFDAC urged the public to report suspected adverse drug reactions through official channels like the Med Safety App, rather than spreading unverified claims.
- The clarification, signed by Director-General Prof. Mojisola Adeyeye, aims to counter misinformation and prevent unnecessary public concern.
NAFDAC Dispels Camosunate Ban Rumors
NAFDAC's clear message is that Camosunate not banned Nigeria NAFDAC, ensuring its continued legal availability for prescription and sale.
The National Agency for Food and Drug Administration and Control (NAFDAC) has officially refuted widespread social media allegations suggesting that Camosunate, a commonly used antimalarial medication, has been prohibited in Nigeria. In a definitive statement issued via a press release on a Saturday, the regulatory body unequivocally declared that it has never imposed a ban on Camosunate or any pharmaceutical products containing the artesunate-amodiaquine combination. This NAFDAC Camosunate ban clarification directly addresses and dismisses the circulating reports, urging the Nigerian public to disregard such unverified claims.
Professor Mojisola Adeyeye, the Director-General of NAFDAC, signed the official communication, which aimed to quell public concern stemming from the online misinformation. The agency's intervention came amidst a surge of social media posts asserting that the antimalarial drug was banned due to various reported adverse effects. NAFDAC's clear message is that Camosunate not banned Nigeria NAFDAC, ensuring its continued legal availability for prescription and sale.
Understanding Adverse Drug Reactions and Reporting
NAFDAC further elaborated that some of the symptoms cited in the viral social media claims could, in fact, be recognized side effects associated with Camosunate. The agency specifically listed nausea, vomiting, diarrhea, abdominal pain, headache, dizziness, drowsiness, and loss of appetite as known potential reactions to the medication. However, NAFDAC strongly emphasized that any suspected Camosunate adverse drug reactions NAFDAC should be formally reported to the agency for thorough assessment, rather than being disseminated as unsubstantiated claims of a ban.
This directive underscores the critical importance of established channels for pharmacovigilance within Nigeria antimalarial drug regulation. Both the general public and healthcare professionals are actively encouraged to submit reports of any suspected adverse reactions through the NAFDAC Med Safety App, which is accessible on both Android and iOS platforms. Alternatively, individuals can report incidents directly at the nearest NAFDAC office, ensuring that legitimate concerns are properly documented and evaluated by the appropriate regulatory authority.
The Peril of Misinformation in Public Health
The proliferation of unverified information, particularly concerning public health matters, poses a significant risk, as highlighted by NAFDAC's recent clarification. The agency explicitly urged Nigerians to cease the circulation of false claims regarding Camosunate, especially across social media platforms. NAFDAC issued a stern warning against the propagation of unverified information about any medicine, emphasizing the potential for unnecessary public alarm and confusion.
To counteract the spread of misinformation, NAFDAC appealed to individuals who had previously shared the erroneous ban claims to actively disseminate the official clarification through the same channels. This proactive measure aims to ensure that accurate information reaches the same audience, thereby preventing undue public concern and reinforcing trust in regulatory pronouncements. The agency's firm stance underscores its commitment to public safety and the integrity of pharmaceutical information in Nigeria.
Practical Implications
Lawyers advising pharmaceutical companies or healthcare providers should note NAFDAC's explicit clarification that Camosunate and artesunate-amodiaquine combinations are not banned in Nigeria, ensuring continued legal prescription and sale. Compliance officers should reinforce proper adverse drug reaction reporting mechanisms to NAFDAC, as emphasized by the agency, rather than relying on unverified social media claims.
Source
How does this affect you?
Get an AI analysis of this article grounded in your jurisdictions, practice areas, and any policy documents you've uploaded to Wansom.
Finish Reading the Full Story and the Expert Analysis.
Get the latest legal & regulatory intelligence in Nigeria
Wansom is AI and can make mistakes.
